1. Home
  2. ELA vs NKTX Comparison

ELA vs NKTX Comparison

Compare ELA & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELA
  • NKTX
  • Stock Information
  • Founded
  • ELA 1965
  • NKTX 2015
  • Country
  • ELA United States
  • NKTX United States
  • Employees
  • ELA N/A
  • NKTX N/A
  • Industry
  • ELA Consumer Specialties
  • NKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELA Consumer Discretionary
  • NKTX Health Care
  • Exchange
  • ELA Nasdaq
  • NKTX Nasdaq
  • Market Cap
  • ELA 175.2M
  • NKTX 170.8M
  • IPO Year
  • ELA N/A
  • NKTX 2020
  • Fundamental
  • Price
  • ELA $6.39
  • NKTX $1.85
  • Analyst Decision
  • ELA Strong Buy
  • NKTX Strong Buy
  • Analyst Count
  • ELA 1
  • NKTX 6
  • Target Price
  • ELA $7.00
  • NKTX $15.00
  • AVG Volume (30 Days)
  • ELA 20.5K
  • NKTX 2.4M
  • Earning Date
  • ELA 03-26-2025
  • NKTX 03-26-2025
  • Dividend Yield
  • ELA N/A
  • NKTX N/A
  • EPS Growth
  • ELA N/A
  • NKTX N/A
  • EPS
  • ELA 0.26
  • NKTX N/A
  • Revenue
  • ELA $180,376,229.00
  • NKTX N/A
  • Revenue This Year
  • ELA $1.61
  • NKTX N/A
  • Revenue Next Year
  • ELA $6.30
  • NKTX N/A
  • P/E Ratio
  • ELA $24.76
  • NKTX N/A
  • Revenue Growth
  • ELA 2.92
  • NKTX N/A
  • 52 Week Low
  • ELA $4.20
  • NKTX $1.31
  • 52 Week High
  • ELA $7.88
  • NKTX $10.48
  • Technical
  • Relative Strength Index (RSI)
  • ELA 58.35
  • NKTX 52.75
  • Support Level
  • ELA $5.43
  • NKTX $1.76
  • Resistance Level
  • ELA $6.66
  • NKTX $2.34
  • Average True Range (ATR)
  • ELA 0.28
  • NKTX 0.16
  • MACD
  • ELA 0.15
  • NKTX 0.06
  • Stochastic Oscillator
  • ELA 82.69
  • NKTX 51.94

About ELA Envela Corporation

Envela Corp and its subsidiaries engage in diverse business activities within the recommerce sector. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

About NKTX Nkarta Inc.

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Share on Social Networks: